ClinicalTrials.gg
TerminatedNCT04157088DaroAcTUpdated Aug 4, 2023Results posted

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

A Phase 2 interventional study of Darolutamide (Nubeqa, BAY1841788) and Enzalutamide in Prostatic Cancer, Castration-Resistant, sponsored by Bayer. Terminated at 7 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-04.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Why this study was terminated
The results of the lead-in phase did not fulfill the criteria set for moving into the randomized phase

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 17 open to participants now, 23 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.

Enrollment
31st of 42
30 · median 91
Started
2019
with 4 others
Phase 2
9 of 50
1 open now
Registered
16th of 50
by date
Lead sponsor
2 of 50
Bayer

Among the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 31st largest by enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2019, is one of 9 in phase 2, and was the 16th registered.

Prostatic Neoplasms, Castration-Resistant

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

17 of the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, or all of them as a file.
02

Study summary

Researchers in this study want to compare the effects of drug darolutamide and drug enzalutamide on physical function, including balance and daily activity, in patients with castration-resistant prostate cancer (CRPC). Both darolutamide and enzalutamide are approved AR inhibitors used for the treatment of patients with CRPC. AR inhibitor is a substance that keeps androgens (male sex hormones) from binding to proteins called androgen receptors, which are found in normal prostate cells, some prostate cancer cells, and in some other cells. Preventing this binding blocks the effects of these hormones in the body and therefore keeps prostate cancer cells from growing. Patients participating this study will receive either darolutamide or enzalutamide tablets. To evaluate the physical function, patients will be asked to make some movements like rising from a chair, walking three meters, etc. Additionally, researchers also want to find out the survival of patients and if patients have fatigue (feeling tired), cognitive (learning and thinking) problems, or other medical problems during the trial. Brand name of darolutamide is Nubeqa; brand name of enzalutamide is Xtandi.

03

Conditions studied

  • Prostatic Cancer, Castration-Resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 years of age inclusive or older at the time of signing the .
  • Participants who have:

    • or cytologically confirmed adenocarcinoma of prostate, CRPC (Castration-resistant prostate cancer) defined by disease progression despite ADT (Androgen deprivation therapy) and may present as either a confirmed rise in serum PSA (Prostate-specific antigen) levels (as defined by PCWG3 (Prostate Cancer Working Group)), the progression of pre-existing disease, and/or the appearance of new . Metastatic and non-metastatic CRPC patients will be eligible.
    • (Karnofsky Performance Scale) performance status of ≥80
    • Blood counts at screening: ≥9.0 g/dL, ≥1500/μL, count ≥100,000/μL
    • Screening values of serum (ALT) and/or aspartate aminotransferase (AST) ≤2.5 × (ULN), total ≤1.5 × ULN, creatinine ≤2.0 × ULN
    • of at least 1 year
  • Sex: Male

Exclusion criteria

Exclusion Criteria:

  • Symptomatic local-regional disease that requires medical intervention including moderate/severe urinary obstruction or hydronephrosis with abnormal renal function due to prostate cancer. Participants with visceral will be excluded.
  • Past (within 6 months before the start of study intervention) or concurrent stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, and/or congestive heart failure ( Class III or IV)
  • Prior . Adequately treated basal cell or squamous cell carcinoma of the skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed 3 years before the start of study intervention and from which the participant has been disease free
  • Prior or concurrent central nervous system disease, such as epilepsy, Parkinson's disease, Alzheimer's disease, dementia, or multiple sclerosis
  • Non-ambulatory participants who need a wheelchair. Other assistive devices (e.g., cane or walker) are permitted.
  • limitations in cognitive function and/or physical function, such as >20 seconds in the TUG assessment
  • Prior treatment with any of the following:

    • Second-generation AR inhibitors, such as enzalutamide, apalutamide, or Darolutamide
    • Other AR inhibitors
    • Progression on abiraterone acetate and discontinuation within 6 months before signing the ICF for the study
    • For mCRPC participants: any chemotherapy, and/or >2 prior lines of systemic anticancer treatment. Treatment with an LHRH agonist, LHRH antagonists, or orchidectomy is not counted as systemic treatment with regard to this exclusion criterion.
  • Use of immunotherapy within 28 days before the start of study intervention
  • Treatment with radiotherapy/radiopharmaceuticals within 12 weeks before the start of study intervention
  • Previous participation in other clinical studies within 28 days before the start of study treatment or 5 half-lives of the investigational treatment of the previous study, whichever is longer Diagnostic assessments
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Participants treated with darolutamide

    Drug: Darolutamide (Nubeqa, BAY1841788)

  • Experimental
    Participants treated with enzalutamide

    Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Worsening in TUG Time During the 24- Week Period.

    TUG: Timed Up \& Go. Worsening is defined as an increase of at least 1 second in TUG time from baseline. (The minimum clinically important difference \[MCID\] in TUG time is 1 second

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Number of Participants With an Increase of at Least 1 Second in TUG Time at 12 and 24 Weeks and During the 52 Weeks.

    Worsening was defined as an increase of at least 1 second in TUG time from baseline. Improved was defined at least 1 second decrease from baseline. Stable was defined as change from baseline between less than 1 second increase and less than 1 second decrease.

    Time frame: At 12 week, 24 week and 52 week.

  2. Time to Worsening (Increase of at Least 1 Second) in TUG Time

    At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

    Time frame: From randomization to the first date a participant had a worsening.

  3. Number of Participants With a Worsening in SPPB Total Score at 12 and 24 Weeks and During the 24 Weeks and 52 Weeks From Baseline.

    The SPPB is a group of measures that combines the results of the gait speed, chair stand and balance tests. The composite SPPB score ranges from 0 (worst performance) to 12 (best performance)

    Time frame: At 12 and 24 weeks and during the 24 weeks and 52 weeks from baseline

  4. Mean Change From Baseline in Daily Physical Activity as Assessed by CPM, at 12 and 24 Weeks, and During the 24 Weeks and 52 Weeks From Baseline.

    Participants required at least 2 valid days to be included in the analysis at each visit. 'Valid' is defined as at least 10 awake wear hours. CPM for each valid day is defined as 'awake wear-filtered total vector magnitude counts' divided by 'awake wear minutes''. A participant's CPM at each visit is the average of daily CPM.

    Time frame: At 12 week, 24 week and 52 week

  5. Mean Change From Baseline in Accelerometer-assessed Proportion of Time Spent in Light to Vigorous Physical Activity Based on a Threshold of >100 Activity Counts Per Minute.

    At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

    Time frame: At 12, 24, and 52 weeks for the randomization phase

  6. Number of Participants With a Decline in Cognitive Function During the 24 Weeks and 52 Weeks From Baseline, as Assessed by HVLT-R.

    The HVLT-R is a learning and memory test, in which the participant is asked to learn and recall a list of 12 words over three trials. The HVLT-R TR (total score) score ranges from 0 to 36, where higher scores indicated greater verbal learning and recall. The HVLT-R DR (delayed recall) score ranges from 0 to 12, where higher scores indicated greater verbal learning and recall. The HVLT-R RECOG (Delayed Recognition) score ranges from -12 to 12, where higher scores indicated better performance.

    Time frame: During the 24 weeks and 52 weeks from baseline.

  7. Number of Participants With a Decline in Cognitive Function During the 24 Weeks and 52 Weeks From Baseline, as Assessed by TMT.

    TMT Part A (TMTA) is timed up to a maximum of 3 minutes, and TMT Part B (TMTB) is timed up to a maximum of 5 minutes. The lower score indicated the better performance.

    Time frame: During the 24 weeks and 52 weeks from baseline.

  8. Number of Participants With a Decline in Cognitive Function During the 24 Weeks and 52 Weeks From Baseline, as Assessed by COWA.

    The COWA test assessed lexical fluency. Given a specific letter of the alphabet, participants were required to produce as many words as possible that begin with that letter. There were two alternate forms of the COWA, each with three unique letter exemplars. The lowest possible score is zero, meaning no words could be produced. There is no limit to the higher end of the scale given that participants can produce as many words as possible for each of the three letters. Higher scores indicate greater word retrieval and better cognitive function.

    Time frame: During the 24 weeks and 52 weeks from baseline.

  9. Number of Participants With a Decline Using a Selected Domain of Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog).

    FACT-Cog with a range of 0-28 points, higher score is better. Decline was defined as a decrease of \>10 points during the 24 weeks and 52 weeks from baseline.

    Time frame: During the 24 weeks and 52 weeks from baseline.

  10. Number of Participants With a Worsening of Fatigue During the 24 Weeks and 52 Weeks.

    At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

    Time frame: Up to 52 weeks in randomization phase.

  11. Number of Participants With an Increase of at Least 1 Point in Fatigue Interference by 24 Weeks and 52 Weeks From Baseline (Based on Items 4A-F of the BFI)

    Fatigue Interference decline is defined as an increase of at least 1 point in any Fatigue Interference from baseline. BFI: Brief Fatigue Inventory. BFI is a 5 minute self-assessment tool that identifies fatigue in cancer participants over a 24-hour period.

    Time frame: At 24 weeks and 52 weeks

  12. Number of Participants With a Worsening in Scores in the PHQ-9 During the 24 Weeks and 52 Weeks From Baseline.

    At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

    Time frame: Up to 52 weeks in randomization phase

  13. Number of Participants With Treatment Emergent AEs, SAEs, and AEs Leading to Study Intervention Discontinuation

    Treatment-Emergent Adverse Events (TEAEs) were defined as any events arising or worsening after the first dose of study drug until 30 days after last dose. SAEs: Serious adverse events

    Time frame: Up to 52 weeks

  14. Number of Participants With AEs of Interest, Including Falls, Fractures, and Hypothyroidism

    AEs of interest were followed up regardless of causality or relationship to study intervention.

    Time frame: Up to 52 weeks

  15. Time to Deterioration of Karnofsky Performance Scale (KPS) Defined as at Least a 10 Point Decline From Baseline.

    At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

    Time frame: From randomization to the first date the participant had had a decline in KPS of at least 10 points.

  16. Number of Participants With Treatment Exposure of the Study Intervention Including Time on Treatment

    A total of 30 participants received treatment with darolutamide 600 mg twice daily in the lead-in phase of the study, comprising the safety evaluable population. No participant received either darolutamide or enzalutamide in the randomized phase of the study as the study was terminated prematurely prior to the initiation of the randomized phase of the study.

    Time frame: Up to 52 weeks

  17. Number of Participants With Dose Reductions of Study Intervention

    At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

    Time frame: Up to 52 weeks in randomization phase

  18. Time to Prostate-specific Antigen (PSA) Progression (as Per Prostate Cancer Working Group [PCWG3] Criteria)

    At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

    Time frame: From randomization to the time when the criteria for PSA progression (according to PCWG3) was met, up to 52 weeks.

  19. Survival Status

    At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

    Time frame: Up to 52 weeks in randomization phase

07

Results

Posted Aug 4, 2023
Limitations and caveats
A total of 30 participants received treatment with darolutamide 600 mg twice daily in the lead in phase of the study, comprising the safety evaluable population. No participant received either darolutamide or enzalutamide in the randomized phase of the study as the study was terminated prematurely prior to the initiation of the randomized phase of the study.

Participant flow

The study was conducted at 7 centers in United States of America (USA) between 17 Dec 2019 (First participant first visit) and 08 JUL 2022 (Last participant last visit).

Participant flow — Overall Study
MilestoneParticipants Treated With Darolutamide
Started30
Received treatment30
Participants off-study30
Completed0
Not completed30
Withdrew: Study terminated by sponsor23
Withdrew: Withdrawal by subject4
Withdrew: Lost to follow-up2
Withdrew: Death1

Outcome measures

PrimaryNumber of Participants With a Worsening in TUG Time During the 24- Week Period.

TUG: Timed Up \& Go. Worsening is defined as an increase of at least 1 second in TUG time from baseline. (The minimum clinically important difference \[MCID\] in TUG time is 1 second

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With a Worsening in TUG Time During the 24- Week Period.
ParticipantsParticipants Treated With Darolutamide
At week 125
At week 245
During the 24-week period8
SecondaryNumber of Participants With an Increase of at Least 1 Second in TUG Time at 12 and 24 Weeks and During the 52 Weeks.

Worsening was defined as an increase of at least 1 second in TUG time from baseline. Improved was defined at least 1 second decrease from baseline. Stable was defined as change from baseline between less than 1 second increase and less than 1 second decrease.

Time frame:
At 12 week, 24 week and 52 week.
Reported as:
Count of participants · Participants
Number of Participants With an Increase of at Least 1 Second in TUG Time at 12 and 24 Weeks and During the 52 Weeks.
ParticipantsParticipants Treated With Darolutamide
At week 12_Stable15
At week 12_Worsen5
At week 12_ Improved2
At week 24_Stable17
At week 24_Worsen5
At week 24_ Improved1
At week 52_Stable14
At week 52_Worsen5
At week 52_ Improved0
SecondaryTime to Worsening (Increase of at Least 1 Second) in TUG Time

At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

Time frame:
From randomization to the first date a participant had a worsening.

No measurements were reported for this outcome.

SecondaryNumber of Participants With a Worsening in SPPB Total Score at 12 and 24 Weeks and During the 24 Weeks and 52 Weeks From Baseline.

The SPPB is a group of measures that combines the results of the gait speed, chair stand and balance tests. The composite SPPB score ranges from 0 (worst performance) to 12 (best performance)

Time frame:
At 12 and 24 weeks and during the 24 weeks and 52 weeks from baseline
Reported as:
Number · Participants
Number of Participants With a Worsening in SPPB Total Score at 12 and 24 Weeks and During the 24 Weeks and 52 Weeks From Baseline.
ParticipantsParticipants Treated With Darolutamide
At week 123
At week 248
At week 527
SecondaryMean Change From Baseline in Daily Physical Activity as Assessed by CPM, at 12 and 24 Weeks, and During the 24 Weeks and 52 Weeks From Baseline.

Participants required at least 2 valid days to be included in the analysis at each visit. 'Valid' is defined as at least 10 awake wear hours. CPM for each valid day is defined as 'awake wear-filtered total vector magnitude counts' divided by 'awake wear minutes''. A participant's CPM at each visit is the average of daily CPM.

Time frame:
At 12 week, 24 week and 52 week
Reported as:
Mean · Mean counts per minute
Mean Change From Baseline in Daily Physical Activity as Assessed by CPM, at 12 and 24 Weeks, and During the 24 Weeks and 52 Weeks From Baseline.
Mean counts per minuteParticipants Treated With Darolutamide
At week 1260.04 ± 266.480
At week 2483.74 ± 455.580
At week 52-37.73 ± 304.621
SecondaryMean Change From Baseline in Accelerometer-assessed Proportion of Time Spent in Light to Vigorous Physical Activity Based on a Threshold of >100 Activity Counts Per Minute.

At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

Time frame:
At 12, 24, and 52 weeks for the randomization phase

No measurements were reported for this outcome.

SecondaryNumber of Participants With a Decline in Cognitive Function During the 24 Weeks and 52 Weeks From Baseline, as Assessed by HVLT-R.

The HVLT-R is a learning and memory test, in which the participant is asked to learn and recall a list of 12 words over three trials. The HVLT-R TR (total score) score ranges from 0 to 36, where higher scores indicated greater verbal learning and recall. The HVLT-R DR (delayed recall) score ranges from 0 to 12, where higher scores indicated greater verbal learning and recall. The HVLT-R RECOG (Delayed Recognition) score ranges from -12 to 12, where higher scores indicated better performance.

Time frame:
During the 24 weeks and 52 weeks from baseline.
Reported as:
Number · Participants
Number of Participants With a Decline in Cognitive Function During the 24 Weeks and 52 Weeks From Baseline, as Assessed by HVLT-R.
ParticipantsParticipants Treated With Darolutamide
HVLT-R TR_At week 245
HVLT-R TR_At week 525
HVLT-R DR_At week 244
HVLT-R DR_At week 523
HVLT-R RECOG_At week 245
HVLT-R RECOG_At week 523
SecondaryNumber of Participants With a Decline in Cognitive Function During the 24 Weeks and 52 Weeks From Baseline, as Assessed by TMT.

TMT Part A (TMTA) is timed up to a maximum of 3 minutes, and TMT Part B (TMTB) is timed up to a maximum of 5 minutes. The lower score indicated the better performance.

Time frame:
During the 24 weeks and 52 weeks from baseline.
Reported as:
Number · Participants
Number of Participants With a Decline in Cognitive Function During the 24 Weeks and 52 Weeks From Baseline, as Assessed by TMT.
ParticipantsParticipants Treated With Darolutamide
TMTA_At week 245
TMTA_At week 523
TMTB_At week 246
TMTB_At week 524
SecondaryNumber of Participants With a Decline in Cognitive Function During the 24 Weeks and 52 Weeks From Baseline, as Assessed by COWA.

The COWA test assessed lexical fluency. Given a specific letter of the alphabet, participants were required to produce as many words as possible that begin with that letter. There were two alternate forms of the COWA, each with three unique letter exemplars. The lowest possible score is zero, meaning no words could be produced. There is no limit to the higher end of the scale given that participants can produce as many words as possible for each of the three letters. Higher scores indicate greater word retrieval and better cognitive function.

Time frame:
During the 24 weeks and 52 weeks from baseline.
Reported as:
Number · Participants
Number of Participants With a Decline in Cognitive Function During the 24 Weeks and 52 Weeks From Baseline, as Assessed by COWA.
ParticipantsParticipants Treated With Darolutamide
At week 243
At week 522
SecondaryNumber of Participants With a Decline Using a Selected Domain of Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog).

FACT-Cog with a range of 0-28 points, higher score is better. Decline was defined as a decrease of \>10 points during the 24 weeks and 52 weeks from baseline.

Time frame:
During the 24 weeks and 52 weeks from baseline.
Reported as:
Number · Participants
Number of Participants With a Decline Using a Selected Domain of Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog).
ParticipantsParticipants Treated With Darolutamide
During the 24-week period0
During the 52-week period3
SecondaryNumber of Participants With a Worsening of Fatigue During the 24 Weeks and 52 Weeks.

At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

Time frame:
Up to 52 weeks in randomization phase.

No measurements were reported for this outcome.

SecondaryNumber of Participants With an Increase of at Least 1 Point in Fatigue Interference by 24 Weeks and 52 Weeks From Baseline (Based on Items 4A-F of the BFI)

Fatigue Interference decline is defined as an increase of at least 1 point in any Fatigue Interference from baseline. BFI: Brief Fatigue Inventory. BFI is a 5 minute self-assessment tool that identifies fatigue in cancer participants over a 24-hour period.

Time frame:
At 24 weeks and 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With an Increase of at Least 1 Point in Fatigue Interference by 24 Weeks and 52 Weeks From Baseline (Based on Items 4A-F of the BFI)
ParticipantsParticipants Treated With Darolutamide
During the 12 week period10 (17.9 to 54.3)
During the 24 week period12 (23.5 to 61.1)
During the 52 week period13 (26.4 to 64.3)
SecondaryNumber of Participants With a Worsening in Scores in the PHQ-9 During the 24 Weeks and 52 Weeks From Baseline.

At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

Time frame:
Up to 52 weeks in randomization phase

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Emergent AEs, SAEs, and AEs Leading to Study Intervention Discontinuation

Treatment-Emergent Adverse Events (TEAEs) were defined as any events arising or worsening after the first dose of study drug until 30 days after last dose. SAEs: Serious adverse events

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent AEs, SAEs, and AEs Leading to Study Intervention Discontinuation
ParticipantsParticipants Treated With Darolutamide
TEAEs26
SAEs6
AEs leading to study intervention discontinuation3
SecondaryNumber of Participants With AEs of Interest, Including Falls, Fractures, and Hypothyroidism

AEs of interest were followed up regardless of causality or relationship to study intervention.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs of Interest, Including Falls, Fractures, and Hypothyroidism
ParticipantsParticipants Treated With Darolutamide
Falls1
Fractures1
Hypothyroidism0
SecondaryTime to Deterioration of Karnofsky Performance Scale (KPS) Defined as at Least a 10 Point Decline From Baseline.

At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

Time frame:
From randomization to the first date the participant had had a decline in KPS of at least 10 points.

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Exposure of the Study Intervention Including Time on Treatment

A total of 30 participants received treatment with darolutamide 600 mg twice daily in the lead-in phase of the study, comprising the safety evaluable population. No participant received either darolutamide or enzalutamide in the randomized phase of the study as the study was terminated prematurely prior to the initiation of the randomized phase of the study.

Time frame:
Up to 52 weeks
Reported as:
Number · Participants
Number of Participants With Treatment Exposure of the Study Intervention Including Time on Treatment
ParticipantsParticipants Treated With Darolutamide
Number of Participants With Treatment Exposure of the Study Intervention Including Time on Treatment30
SecondaryNumber of Participants With Dose Reductions of Study Intervention

At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

Time frame:
Up to 52 weeks in randomization phase

No measurements were reported for this outcome.

SecondaryTime to Prostate-specific Antigen (PSA) Progression (as Per Prostate Cancer Working Group [PCWG3] Criteria)

At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

Time frame:
From randomization to the time when the criteria for PSA progression (according to PCWG3) was met, up to 52 weeks.

No measurements were reported for this outcome.

SecondarySurvival Status

At the end of the lead-in phase, the overall feasibility of the study execution was assessed and decided not to proceed with the randomized phase. Therefore, data on this outcome which needed to be collected in the randomized phase was unavailable.

Time frame:
Up to 52 weeks in randomization phase

No measurements were reported for this outcome.

Adverse events

Collected over Timeframe for TEAEs: after the first dose of study drug until 30 days after last dose, with a maximum duration of 815 days. Timeframe for the all-cause mortality: All deaths that occurred at any time during the study before the last contact, with a maximum duration of 847 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Treated With Darolutamide1/30 (3.3%)6/30 (20%)21/30 (70%)
Most frequent serious events
Most frequent serious events
EventParticipants Treated With Darolutamide
Cardiac failureCardiac disorders1/30
Aortic valve diseaseCardiac disorders1/30
COVID-19Infections and infestations1/30
Spinal fractureInjury, poisoning and procedural complications1/30
Spinal cord compressionNervous system disorders1/30
Acute kidney injuryRenal and urinary disorders1/30
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/30
Most frequent other events
Showing 10 of 15
Most frequent other events
EventParticipants Treated With Darolutamide
FatigueGeneral disorders8/30
HaematuriaRenal and urinary disorders5/30
DizzinessNervous system disorders4/30
Back painMusculoskeletal and connective tissue disorders3/30
Pain in extremityMusculoskeletal and connective tissue disorders3/30
Rash maculo-papularSkin and subcutaneous tissue disorders3/30
ConstipationGastrointestinal disorders2/30
Oedema peripheralGeneral disorders2/30
COVID-19Infections and infestations2/30
DehydrationMetabolism and nutrition disorders2/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Participants Treated With Darolutamide
Mean75.6 ± 8.18
Sex: Female, Male
Sex: Female, Male(Participants)Participants Treated With Darolutamide
Female0
Male30
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants Treated With Darolutamide
Hispanic or Latino1
Not Hispanic or Latino26
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants Treated With Darolutamide
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American7
White14
More than one race0
Unknown or Not Reported9
Short Physical Performance Battery (SPPB)
Short Physical Performance Battery (SPPB)(units on a scale)Participants Treated With Darolutamide
Mean8.17 ± 1.577
Counts per minute (CPM)
Counts per minute (CPM)(Mean count per minute)Participants Treated With Darolutamide
Mean1900.4 ± 448.442
Cognitive function: Hopkins Verbal Learning Test Revised (HVLT-R)
Cognitive function: Hopkins Verbal Learning Test Revised (HVLT-R)(units on a scale)Participants Treated With Darolutamide
HVLT-R TR19.2 ± 6.24
HVLT-R DR7.1 ± 3.14
HVLT-R RECOG9.1 ± 2.48
Cognitive function: Trail Making Test (TMT)
Cognitive function: Trail Making Test (TMT)(seconds)Participants Treated With Darolutamide
TMTA50.4 ± 31.46
TMTB113.0 ± 64.17

1 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • Oregon Health and Science University
    Portland, Maine 97239, United States
  • New Jersey Urology, LLC
    Voorhees, New Jersey 08043, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • MidLantic Urology - Bala Cynwyd
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Bon Secours St. Francis Hospital
    Greenville, South Carolina 29607, United States
  • Carolina Urological Research Center
    Myrtle Beach, South Carolina 29579, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jul 2022, 30 months.

Results were first posted in Aug 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2019
First posted
Nov 8, 2019
StartActual
Dec 17, 2019
Primary completionActual
Jul 8, 2022
CompletionActual
Jul 8, 2022
Results first posted
Aug 4, 2023
Last update
Aug 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04157088
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 8, 2019
Start date
Dec 17, 2019
Primary completion
Jul 8, 2022
Completion
Jul 8, 2022
Results posted
Aug 4, 2023
Last update
Aug 4, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darolutamide · Enzalutamide

Start the discussion